Cover Image
市場調查報告書

Beta Pharma, Inc.:產品平台分析

Beta Pharma, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319965
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
Beta Pharma, Inc.:產品平台分析 Beta Pharma, Inc. - Product Pipeline Review - 2015
出版日期: 2015年02月24日 內容資訊: 英文 26 Pages
簡介

Beta Pharma, Inc. 是專門開發並商品化後期階段癌症之劃時代治療方法的製藥公司。該公司的產品適用於治療非小細胞肺癌、轉移性腎細胞癌症、去勢療法無效前列腺癌,胰臟癌症等疾病。

本報告提供Beta Pharma, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Beta Pharma, Inc.的基本資料

  • Beta Pharma, Inc.概要
  • 主要資訊
  • 企業資料

Beta Pharma, Inc. :R&D概要

  • 主要的治療範圍

Beta Pharma, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Beta Pharma, Inc. :開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 藥物研發中的產品/聯合治療模式

Beta Pharma, Inc. :藥物簡介

  • icotinib hydrochloride
  • BPI-0403
  • BPI-3119
  • BPI-5143
  • BPI-4039

Beta Pharma, Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Beta Pharma, Inc. :暫停中的計劃

Beta Pharma, Inc. :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06803CDB

Summary

Global Markets Direct's, 'Beta Pharma, Inc. - Product Pipeline Review - 2015', provides an overview of the Beta Pharma, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Beta Pharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Beta Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Beta Pharma, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Beta Pharma, Inc.'s pipeline products

Reasons to buy

  • Evaluate Beta Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Beta Pharma, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Beta Pharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Beta Pharma, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Beta Pharma, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Beta Pharma, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Beta Pharma, Inc. Snapshot
    • Beta Pharma, Inc. Overview
    • Key Information
    • Key Facts
  • Beta Pharma, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Beta Pharma, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Beta Pharma, Inc. - Pipeline Products Glance
    • Beta Pharma, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Beta Pharma, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Beta Pharma, Inc. - Drug Profiles
    • icotinib hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BPI-0403
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BPI-3119
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BPI-5143
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BPI-4039
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Beta Pharma, Inc. - Pipeline Analysis
    • Beta Pharma, Inc. - Pipeline Products by Target
    • Beta Pharma, Inc. - Pipeline Products by Route of Administration
    • Beta Pharma, Inc. - Pipeline Products by Molecule Type
    • Beta Pharma, Inc. - Pipeline Products by Mechanism of Action
  • Beta Pharma, Inc. - Dormant Projects
  • Beta Pharma, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Beta Pharma, Inc., Key Information
  • Beta Pharma, Inc., Key Facts
  • Beta Pharma, Inc. - Pipeline by Indication, 2015
  • Beta Pharma, Inc. - Pipeline by Stage of Development, 2015
  • Beta Pharma, Inc. - Monotherapy Products in Pipeline, 2015
  • Beta Pharma, Inc. - Partnered Products in Pipeline, 2015
  • Beta Pharma, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Beta Pharma, Inc. - Phase I, 2015
  • Beta Pharma, Inc. - Preclinical, 2015
  • Beta Pharma, Inc. - Discovery, 2015
  • Beta Pharma, Inc. - Pipeline by Target, 2015
  • Beta Pharma, Inc. - Pipeline by Route of Administration, 2015
  • Beta Pharma, Inc. - Pipeline by Molecule Type, 2015
  • Beta Pharma, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Beta Pharma, Inc. - Dormant Developmental Projects,2015
  • Beta Pharma, Inc., Subsidiaries

List of Figures

  • Beta Pharma, Inc. - Pipeline by Top 10 Indication, 2015
  • Beta Pharma, Inc. - Pipeline by Stage of Development, 2015
  • Beta Pharma, Inc. - Monotherapy Products in Pipeline, 2015
  • Beta Pharma, Inc. - Partnered Products in Pipeline, 2015
  • Beta Pharma, Inc. - Pipeline by Top 10 Target, 2015
  • Beta Pharma, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top